

Prevalence and Odds of Developing Sexual Dysfunction in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis

Zahra Shahraki; M.D.¹, Mohsen Rastkar; M.D.², Elham Rastkar; M.D.³, Aida Mohamadi; M.D.⁴, Mozhddeh Mohammadghasemi; M.D.⁵, Mahsa Ghajarzadeh; M.D.⁴

1 Zabol Medicinal Plants Research Center, Zabol University of Medical Sciences, Zabol, Iran

2 Students Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran

3 Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

4 Universal Council of Epidemiology (UCE), Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences, Tehran, Iran

5 Faculty of Dentistry, Zahedan University of Medical Sciences, Zahedan, Iran

Received September 2025; Revised and accepted December 2025

Abstract

Objective: Women with polycystic ovary syndrome (PCO) suffer from a wide range of psychological difficulties such as sexual dysfunction (SD). In different countries, sexual dysfunction has been evaluated in women with PCO, but the results differ between studies. So, we designed this systematic review and meta-analysis to estimate the pooled prevalence of sexual dysfunction and to assess the odds of SD among women with PCO compared with controls.

Materials and methods: PubMed, Scopus, EMBASE, Web of Science, Google Scholar were systematically searched by two independent researchers on December 1st, 2023. Data analysis was done using STATA.

Results: A literature search revealed 1636 records, 84 full-texts were evaluated, and finally, 37 studies remained for systematic review. Most studies were published in 2023, followed by 2022. Most studies were from Iran, followed by Turkey. The prevalence of SD in women with PCO ranged between 4% and 99%, and the pooled prevalence was estimated as 73% (95%CI: 72%-74%, fixed-effect model) ($I^2=0$). The odds of SD in women with PCO ranged between 0.42 and 7.29, and pooled OR was estimated as 2.45 (95%CI: 1.55-3.86, random-effect model) ($I^2=79.9\%$, $P<0.001$). The SMD of total FSFI (case-control) ranged between -2.83, and 0.46, and the pooled SMD was estimated as -0.48 (95% -0.72, -0.25) ($I^2=94.6\%$, $P<0.001$, random-effect model).

Conclusion: This meta-analysis demonstrates a significantly higher prevalence of sexual dysfunction in women with PCO, emphasizing the need for routine sexual health assessment and holistic management, including psychological support, hormonal regulation, and lifestyle interventions.

Keywords: Polycystic Ovary Syndrome; Women; Sexual Dysfunction

Introduction

Polycystic ovary syndrome (PCO) is an endocrine

disorder affecting up to 10% of women of reproductive age (1-3). Physical manifestations such as hirsutism, acne, and menstrual irregularities can lead to psychological complications, including depression, anxiety, low self-esteem, marital and

Correspondence:

Mahsa Ghajarzadeh

Email: m.ghajarzadeh@gmail.com



Copyright © 2025 Tehran University of Medical Sciences. Published by Tehran University of Medical Sciences.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license (<https://creativecommons.org/licenses/by-nc/4.0/>).

Noncommercial uses of the work are permitted, provided the original work is properly cited.

social maladjustments, sexual dysfunction, and an overall impaired quality of life (4-6). The high prevalence of infertility and obesity among women with PCOS may predispose them to sexual dysfunction and negatively impact their overall well-being (7). Conversely, both psychological factors and androgen excess may play a role in the development of sexual dysfunction (SD), with evidence indicating that multiple dimensions of sexual life are adversely affected in women with PCOS(8). Given the inconsistent findings across previous meta-analyses and the recent surge of new data, this study aims to provide an updated pooled estimate of SD prevalence and its domains among women with PCO.

Materials and methods

We followed the referred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 (9).

The inclusion criteria were: We included cross-sectional studies, cohorts, and case-control studies that reported the prevalence of sexual disorders in women with PCO. We only included studies that used the female sexual function index (FSFI) questionnaire.

The exclusion criteria were: Letters to the editor, and case reports were excluded. We also excluded studies that had no clear data regarding the prevalence of sexual disorders. We did not have language restriction.

Information sources: A systematic search of PubMed, Scopus, EMBASE, Web of Science, and Google Scholar was conducted by two independent researchers on December 1, 2023. Conference abstracts and the reference lists of included studies were additionally reviewed to identify any further relevant publications.

Search strategy: (((((((((((((((((((Polycystic Ovary Syndrome[MeSH Terms]) OR (Polycystic Ovary Syndrome[Text Word])) OR (polycystic ovar*[Text Word])) OR (Sclerocystic Ovar*[Text Word])) OR (PCO[Text Word])) OR (PCO[Text Word])) OR (Ovary Syndrome, Polycystic[Text Word])) OR (Syndrome, Polycystic Ovary[Text Word])) OR (Stein-Leventhal Syndrome[Text Word])) OR (Stein Leventhal Syndrome[Text Word])) OR (Syndrome, Stein-Leventhal[Text Word])) OR (Sclerocystic Ovarian Degeneration[Text Word])) OR (Ovarian Degeneration, Sclerocystic[Text Word])) OR (Sclerocystic Ovary Syndrome[Text Word])) OR (Polycystic Ovarian Syndrome[Text Word])) OR

(Ovarian Syndrome, Polycystic[Text Word])) OR (Polycystic Ovary Syndrome 1[Text Word])) OR (Ovary, Sclerocystic[Text Word])) AND (((((((((((((((((((Sexual Dysfunction*[Text Word])) OR (Dysfunction, Sexual[Text Word])) OR (Dysfunctions, Sexual[Text Word])) OR (Disorders, Sexual[Text Word])) OR (Disorder, Sexual[Text Word])) OR (Sexual Disorder*[Text Word])) OR (Dysfunction, Psychosexual[Text Word])) OR (Dysfunctions, Psychosexual[Text Word])) OR (Psychosexual Dysfunction*[Text Word])) OR (Disorder, Psychosexual[Text Word])) OR (Disorders, Psychosexual[Text Word])) OR (Psychosexual Disorder*[Text Word])) OR (Hypoactive Sexual Desire Disorder*[Text Word])) OR (Aversion Disorders, Sexual[Text Word])) OR (Disorders, Sexual Aversion[Text Word])) OR (Sexual Aversion Disorder*[Text Word])) OR (Disorders, Orgasmic[Text Word])) OR (Orgasmic Disorder*[Text Word])) OR (Arousal Disorders, Sexual[Text Word])) OR (Disorders, Sexual Arousal[Text Word])) OR (Sexual Arousal Disorder*[Text Word])) OR (Frigidity[Text Word]))

Selection process, and data collection: After all relevant studies were retrieved by two independent researchers, the results were imported into EndNote, and duplicate records were removed. The titles and abstracts were then screened independently by both researchers, followed by full-text evaluation of the eligible studies. In cases of disagreement regarding study inclusion, a third reviewer resolved the discrepancies. Data extracted by each researcher were entered into an Excel sheet and cross-checked by a third reviewer for accuracy.

Data items: From each included study, the following data were extracted: first author's name, year of publication, country of origin, total sample size, prevalence of sexual dysfunction among women with PCOS, and the reported odds of sexual dysfunction in this population.

Study risk of bias assessment: We assessed the risk of potential bias using the NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE (10, 11).

Effect measures: Standardized mean difference (SMD) was calculated as the effect size

Synthesis methods: All statistical analyses were performed using STATA (Version 14.0; Stata Corp LP, College Station, TX, USA). To determine heterogeneity, Inconsistency (I^2) was calculated. We used the fixed effects model or random-effects model

for meta-analysis if the heterogeneity between study results (I^2) was less than 50% or more than 50%. For studies that provided the mean of FSFI in different PCO groups, we pooled all means for PCO group. When the original data were reported as median and interquartile range (IQR), the median was considered as the mean, and the IQR was converted to standard deviation (SD) using the formula $SD = IQR / 1.35$. The standardized mean difference (SMD) was calculated as the effect size. Publication bias was assessed using a funnel plot, as well as Begg's and Egger's tests. Meta-regression analyses were performed to explore potential sources of heterogeneity among the included studies. The protocol was not registered in the PROSPERO.

Certainty assessment: For each summary estimate, we reported the pooled estimate as well as 95% CI to show certainty.

Results

A literature search revealed 1636 records, 84 full-texts were evaluated, and finally, 37 studies remained for systematic review (Figure 1).

Thirty-seven studies were included. Most studies were published in 2023, followed by 2022. Most studies were from Iran, followed by Turkey. In total

4073 cases, and 3145 controls were evaluated. Mean age, and BMI in PCO group ranged between 23.9-34 years, and 21.6-35.6 kg/m², respectively (Table 1, a and b). We used fixed-effect model for prevalence and random-effect model for other estimates.

The prevalence of SD in women with PCO ranged between 4% and 99%, and the pooled prevalence estimated as 73% (95%CI: 72%-74%) ($I^2=0\%$ justify fixed model use) (Figure 2).

The odds of SD in women with PCO ranged between 0.42 and 7.29, and pooled OR estimated as 2.45 (95% CI: 1.55-3.86) ($I^2=79.9\%$, $P<0.001$) (Figure 3).

The pooled mean of FSFI in PCO group estimated as 24.03 (95% CI: 22.96-25.09) ($I^2=99\%$, $p<0.001$) (Figure 4).

The SMD of total FSFI (case-control) ranged between -2.83, and 0.46, and the pooled SMD estimated as -0.48(95% -0.72, -0.25) ($I^2=94.6\%$, $P<0.001$) (Figure 5).

Funnel plot and Begg and Egger's test results show that there was no evidence of publication bias (Figure 6).

We considered the country of origin as the source of heterogeneity for total FSFI results, and conducted meta-regression analysis.




Figure 1: The flow chart of including studies shows that 37 studies were included for final analysis.

Table 1a: Study characteristics

| Author | Year | Country | Study design | Participants | NOS | Age | BMI | Prevalence |
|-------------------------|------|---------|-----------------|---|-----|---|---|--|
| Uzel et al. (12) | 2021 | Turkey | Case control | 28 cases / 26 controls | 7 | | Case: 29.6±7.1 / Control: 24.7±3.9 | |
| Hashemi et al. (13) | 2014 | Iran | Cross sectional | 535 | 6 | 30.6 ± 5.01 | 27.9 ± 6.1 | 63.5% |
| Kogure et al. (14) | 2019 | Brazil | Cross sectional | 94 | 6 | 28.5±5.2 | 29.1±5.3 | 54.1% |
| Aba et al. (15) | 2022 | Turkey | Case control | 97 cases / 95 controls | 6 | Case: 28.23±4.56 /Control: 29.33±5.61 | Case: 25.08±4.3 /Control: 22.34±3.74 | Case: 74.23% / Control: 44.21% |
| Ferrarsi et al. (16) | 2013 | Brazil | Cross sectional | 24 Obese cases / 24 nonobese cases / 16 obese control / 19 nonobese control | 7 | Obese cases: 26.7 ± 4.6/ nonobese cases: 25.5 ± 5.7/ obese control: 31.7 ± 3.3/ nonobese control: 30.5 ± 5.7 | Obese cases: 34.2 ± 2.8/ nonobese cases: 24.4 ± 3.4/ obese control: 34.9 ± 3.2/ nonobese control: 24.0 ± 2.7 | |
| Shafti et al. (17) | 2016 | Iran | Case control | 129 cases / 125 controls | 6 | Case: 30.10 / Control: 32.79 | | |
| Mojahed et al. (18) | 2023 | Iran | Case control | 106 cases/ 106 controls | 7 | Case: 26.9±5.2 / control: 27.8±6.8 | | Case: 72.6% |
| Akbari Sene et al. (19) | 2021 | Iran | Case control | 116 Infertile PCO / 93 Infertile control | 6 | Infertile PCO: 31.00 ± 5.00 / Infertile control: 34.00 ± 6.00 | Infertile PCO: 26.66 ± 3.85/ Infertile control: 26.58 ± 4.43 | Infertile PCO: 42.2%/ Infertile control: 37.6% |
| Ashraf et al. (20) | 2022 | Iran | Cross sectional | 80 Infertile PCO cases / 160 fertile controls | 6 | Infertile PCO case: 31.94±4.44/ fertile Control: 31.66±1.89 | Infertile PCO case: 27.04±3.24 / fertile Control: 26.13±3.75 | Infertile PCO case: 98.8% / fertile Control: 36.2% |
| Daescu et al. (21) | 2023 | Romania | Cross sectional | 54 | 7 | 26.54 ±2.94 | Median (IQR): 26.55 (23.73–35.50) | 59.3% |
| Deniz and Kehribar (22) | 2020 | Turkey | Case control | 50 PCO cases / 50 PCO cases with infertility / 50 control | 7 | PCO case: 32.0±4.0/ PCO case with infertility: 31.7±3.7/ control: 31.0±4.0 | PCO case: 25.1±2.2 / PCO case with infertility: 27.9±2.9 / control: 25.5±2.3 | |
| Yarjanli et al. (23) | 2022 | Iran | Cross sectional | 95 Phenotype A PCO/ 79 Phenotype B PCO/ 95 Phenotype C PCO/ 95 Phenotype D PCO/ 100 Control | 8 | Phenotype A PCO: 29.62±5.44 / Phenotype B PCO: 31.32±4.84 / Phenotype C PCO: 30.95±5.13 / Phenotype D PCO: 31.18±5.28 / Control: 29.95±4.10 | Phenotype A PCO: 31.32±4.84 / Phenotype B PCO: 26.01± 31.55 / Phenotype C PCO: 25.96±3.99 / Phenotype D PCO: 25.87±3.59 / Control: 26.98±4032 | |
| Lara et al. (24) | 2015 | Brazil | Case control | 43 Cases / 51 Controls | 7 | Case: 27.80 ± 5.34 / Control: 29.74 ± 5.26 | Case: 27.91 ± 5.51/ Control: 25.99 ±5.49 | Case: 69.7% / Control: 62.7% |
| Mantzou et al. (25) | 2021 | Greece | Case control | 76 cases / 133 controls | 6 | Case: 22.17 ± 2.51/ Control: 21.62 ± 1.93 | Case: 23.97 ± 5.39 / control: 22.1 ± 4.0 | |
| Battaglia et al. (26) | 2008 | Italy | Cross sectional | 25 cases: / 11 Control | 6 | Case: 27.7 ± 5.4 / Control: 30.7 ± 3.9 | Case: 21.6 ± 2.4 / Control: 21.2 ± 2.0 | Case: 4% / Control: 11% |
| Battaglia et al. (26) | 2008 | Italy | Cross sectional | 25 cases: / 11 Control | 6 | Case: 27.7 ± 5.4 / Control: 30.7 ± 3.9 | Case: 21.6 ± 2.4 / Control: 21.2 ± 2.0 | Case: 4% / Control: 11% |

Table 1a: Study characteristics (continue)

| Author | Year | Country | Study design | Participants | NOS | Age | BMI | Prevalence |
|----------------------------|------|-----------------|-----------------|--|-----|---|---|--|
| Drosdzol et al. (27) | 2007 | Poland | Cross sectional | 50 cases / 40 controls | 6 | Case: 28.9±5.6 / Control: 30.5±5.3 | Case: 24.6±3.8 / Control: 22.1±2.9 | Case: 28.6% / Control: 10.5% |
| Ercan et al. (28) | 2013 | Turkey | Case control | 32 cases / 32 controls | 6 | Case: 27.4±3.3 / Control: 27.0±3.2 | Case: 25.5±3.0 / Control: 24.4±3.6 | Case: 25% / Control: 19% |
| Eftekhari et al. (29) | 2014 | Iran | Cross sectional | 130 | 7 | 27.02 ± 4.27 | 26.98 ± 8.4 | 57.7% |
| Veras et al. (30) | 2011 | Brazil | Cross sectional | 88 | 6 | 27.2± 7.3 | | 13.3% |
| Dashti et al. (31) | 2016 | Malaysia | Cross sectional | 16 | 6 | 33.44±5.88 | 28.04±3.34 | 62.5% |
| Pastoor et al. (32) | 2023 | The Netherlands | Case control | 68 cases / 67 controls | 6 | Case: 27.64 ± 5.74 / Control: 25.89 ± 5.69 | Mean (range) Case: 24.79 (17–42) / Control: 23.55 (18–35) | Case: 41.2% / Control: 11.9% |
| Kirmizi et al. (33) | 2020 | Turkey | Cross sectional | Fertile PCO: 3.86 ± 1.34 / Infertile PCO: 4.2 ± 1.05 / fertile control: 3.69 ± 0.92 | 6 | Fertile PCO: 23.8 ± 4.05 / Infertile PCO: 26.13 ± 4.66 / fertile control: 31.9 ± 4.73 | Fertile PCO: 26.72 ± 3.77 / Infertile PCO: 26.19 ± 6.02 / fertile control: 25.08 ± 4.84 | Fertile PCO: 45% / Infertile PCO: 50% / fertile control: 36.7% |
| Noroozzadeh et al. (34) | 2016 | Iran | Cross sectional | 63 cases / 216 controls | 6 | Case: 33.6±7.2/ Control: 36.3±6.9 | Case: 27.14± 5.74/ Control: 27.35± 4.95 | Case: 44.4% / Control: 36.1% |
| Fliegner et al. (35) | 2019 | Germany | Cross sectional | 44 | 6 | Median (IQR): 28.5(27-30.8) | Median (IQR): 25.8(21.2-32.6) | 19.5% |
| Tian et al. (36) | 2023 | China | Cross sectional | 408 Phenotype A PCO/ 114 Phenotype B PCO/ 73 Phenotype C PCO /214 Phenotype D PCO/ 385 Control | 7 | Phenotype A PCO: 26.89±3.95 / Phenotype B PCO: 27.47±3.88 / Phenotype C PCO: 28.17±4.38 / Phenotype D PCO: 27.87±3.91 / Control: 27.56±3.83 | Phenotype A PCO: 26.78±3.89 / Phenotype B PCO: 25.77±4.42 / Phenotype C PCO: 25.06±3.53 / Phenotype D PCO: 23.24±3.70 / Control: 23.35±3.53 | All PCO: 81.11% / Phenotype A PCO: 87.5% / Phenotype B PCO: 82.46% / Phenotype C PCO: 75.34% / Phenotype D PCO: 70.56% / Control: 61.30% |
| Tian et al. (37) | 2021 | China | Cross sectional | 685 | 7 | 29.02±4.17 | 24.48 ±4.47 | 79.56% |
| Diamond et al. (38) | 2017 | US | Cross sectional | 734 Infertile PCO / 860 Unexplained infertility | 6 | Infertile PCO: 28.9±4.3 / Unexplained infertility: 32.2±4.2 | | |
| Kępczyńska-Nyk et al. (39) | 2020 | Poland | Cross sectional | 63 cases / 20 controls | 6 | Case: 26.56 ±5.45/ Control: 30.85 ±6.73 | Case: 27.58 ±6.98/ Control: 24.18 ±4.37 | Case: 33.3% |
| Bazarganipour et al. (40) | 2013 | Iran | Cross sectional | 300 | 7 | 26.56 ± 4.44 | | 16.6% |

Table 1a: Study characteristics (continue)

| Author | Year | Country | Study design | Participants | NOS | Age | BMI | Prevalence |
|---------------------------|------|----------|-----------------|--|-----|--|--|--|
| Bahadori et al. (41) | 2022 | Iran | Cross sectional | 55 Phenotype A PCO / 30 Phenotype B PCO / 56 Phenotype C PCO / 51 Phenotype D PCO / 50 Control | 7 | Phenotype A PCO: 29.18±5.71 / Phenotype B PCO: 31.55±5.68 / Phenotype C PCO: 31.67±5.05 / Phenotype D PCO: 31.28±5.5 / Control: 34.18±4.13 | Phenotype A PCO: 27.21±4.80 / Phenotype B PCO: 26.59±3.85 / Phenotype C PCO: 25.60±3.67 / Phenotype D PCO: 26.45±3.75 / Control: 26.96±3.12 | Phenotype A PCO: 45.5% / Phenotype B PCO: 53.3% / Phenotype C PCO: 42.8% / Phenotype D PCO: 41.1% / Control: 50% |
| Basirat et al. (42) | 2019 | Iran | Case control | 120 Infertile PCO / 120 Infertile control | 6 | Infertile PCO: / Infertile control: | Infertile PCO: / Infertile control: | |
| Fereidooni et al. (43) | 2022 | Iran | Cross sectional | 130 | 6 | 29.74 ± 5.3 | | 60% |
| Benetti-Pinto et al. (44) | 2014 | Brazil | Cross sectional | 56 cases / 102 controls | 6 | Case: 26.9 ± 4.9 / Control: 35.6 ± 7.3 | Case: 31.9 ± 8.5/ Control: 28.5 ± 5.4 | |
| Forouhari et al. (45) | 2019 | Iran | Cross sectional | 32 Fertile PCO / 31 Infertile PCO | 7 | Fertile PCO: 28.33±4.92 / Infertile PCO: 27.81±4.32 | Fertile PCO: 25.57±4.26 / Infertile PCO: 25.25±3.36 | Fertile PCO: 54.5% / infertile PCO: 85.7% |
| Altuntaş et al. (46) | 2022 | Turkey | Cross sectional | 167 All PCO Cases / 72 phenotype A PCO / 42 Phenotype B PCO / 38 Phenotype C PCO / 16 Phenotype D PCO / 73 Controls | 8 | All PCO Cases: 25.87±5.64 / phenotype A PCO: 25.83±5.21 / Phenotype B PCO: 24.78±6.40 / Phenotype C PCO: 25.63±4.97 / Phenotype D PCO: 29.44±6.07 / Control: 27.25±5.85 | All PCO Cases: 29.32±5.60 / phenotype A PCO: 30.84±5.68 / Phenotype B PCO: 29.29±5.30 / Phenotype C PCO: 27.39±5.00 / Phenotype D PCO: 27.73±6.34 / Control: 23.77±4.22 | |
| Gateva et al. (47) | 2012 | Bulgaria | Case control | 16 Obese PCO / 41 lean PCO / 22 obese control | 7 | Obese PCO: 24.9 ± 4.4 / lean PCO: 24.2 ± 4.8 / Obese control: 32.5 ± 8.5 | Obese PCO: 35.6 ± 4.9/ lean PCO: 22.7 ± 3.4 / Obese control: 40.2 ± 9.4 | |
| Davar Tanha et al. (48) | 2023 | Iran | Case control | 100 Cases / 93 Controls | 7 | Case: 29.7±5.4 / Control: 30.4± 4.1 | | Case: 62% / Control: 18.2% |

Table 1b: FSFI domain results

| Desire | Arousal | Lubrication | Orgasm | Satisfaction | Pain | Total FSFI |
|--|--|--|--|--|--|---|
| Case: 2.56±1.27/ Control: 2.58±0.80 | Case: 3.10±1.31 / Control: 2.95±0.98 | Case: 3.54±1.37 / Control: 4.00±0.71 | Case: 3.07±1.42 / Control: 3.43±0.54 | Case: 2.10±1.30 / Control: 2.15±1.02 | Case: 3.16±1.72 / Control: 4.60±1.39 | Case: 18.76±4.77 / Control: 20.92±2.50 |
| 3.3±1.0 | 3.9±1.2 | 4.7±1.2 | 4.2±1.2 | 3.9±1.5 | 4.4±1.7 | 24.5±5.7 |
| Case: 3.41±1.15/ Control: 3.85±1.13 | Case: 2.53±1.21/ Control: 3.19±1.16 | Case: 2.36±0.95/ Control: 3.5±0.69 | Case: 2.49±0.67/ Control: 3.51±0.66 | Case: 2.37±1.07/ Control: 2.43±1.14 | Case: 3.31±1.37/ Control: 4.97±1.17 | Case: 16.65±5.93/ Control: 18.89±6.53 |
| Case: 6.18±1.56 / Control: 6.55±1.68 | Case: 12.74±3.92 / Control: 13.38±4.73 | Case: 13.72±4.13 / Control: 13.92±4.64 | Case: 10.81±3.55 / Control: 11.53±4.12 | Case: 11.40±3.75 / Control: 12.19±4.18 | Case: 10.57±3.82 / Control: 10.80±4.16 | |
| Case: 4.1±0.8 / control: 3.7±1.1 | Case: 3.8±1.6/ control: 3.9±1.4 | Case: 3.5±1.7/ control: 4.4±1.5 | Case: 3.8±1.8/ control: 4.5±1.5 | Case: 3.9±1.7/ control: 4.7±1.2 | Case: 2.9±1.7/ control: 4.3±1.4 | Case: 22.1±7.8/ control: 25.7±7.3 |
| Infertile PCO: 3.78 ± 1.01 / Infertile control: 3.81 ± 1.09 | Infertile PCO: 3.69 ± 1.23 / Infertile control: 3.67 ± 1.32 | Infertile PCO: 4.92 ± 1.15 / Infertile control: 5.07 ± 1.07 | Infertile PCO: 4.52 ± 1.17 / Infertile control: 4.68 ± 0.95 | Infertile PCO: 5.06 ± 1.00 / Infertile control: 5.11 ± 0.95 | Infertile PCO: 5.00 ± 1.09 / Infertile control: 5.04 ± 1.00 | Infertile PCO: 26.97 ± 4.73 / Infertile control: 27.38 ± 3.72 |
| Infertile PCO case: 3.04±0.74/ fertile Control: 4.39±1.14 | Infertile PCO case: 3.21±0.75/ fertile Control: 5.03±1.05 | Infertile PCO case: 3.52±0.80 / fertile Control: 4.99±0.83 | Infertile PCO case: 3.50±0.69 / fertile Control: 4.49±0.81 | Infertile PCO case: 4.16±0.95 / fertile Control: 5.10±0.78 | Infertile PCO case: 4.16±1.22/ fertile Control: 5.05±0.85 | Infertile PCO case: 21.60±2.90/ fertile Control: 29.07±2.50 |
| Median (IQR) 3.60 (3.00–5.40) | Median (IQR) 4.05 (3.00–5.10) | Median (IQR) 4.80 (3.37–5.40) | Median (IQR) 4.00 (2.40–5.20) | Median (IQR) 4.80 (3.30–5.20) | Median (IQR) 4.80 (4.00–6.00) | 25.08 ±4.62 |
| PCO case: 3.63±0.93/ PCO case with infertility: 3.21±0.75 | PCO case: 3.53±0.86 / PCO case with infertility: 3.39±0.71 | PCO case: 3.73±0.77 / PCO case with infertility: 3.2±0.95 | PCO case: 3.52±0.77 / PCO case with infertility: 3.21±0.76 | PCO case: 3.61±0.75/ PCO case with infertility: 3.23±0.72 | PCO case: 3.72±0.73 / PCO case with infertility: 3.13±0.61 | PCO case: 21.71±3.73 / PCO case with infertility: 19.45±4.50 / control: 27.57±4.14 |
| Phenotype A PCO: 3.78±0.90 / Phenotype B PCO: 3.39±0.81 / Phenotype C PCO: 3.63±0.76 / Phenotype D PCO: 3.70±0.98 / Control: 4.36±0.98 | Phenotype A PCO: 4.05±1.08 / Phenotype B PCO: 3.06±1.04 / Phenotype C PCO: 4.02±1.06 / Phenotype D PCO: 3.99±1.03 / Control: 5.85±0.38 | Phenotype A PCO: 4.51±1.01 / Phenotype B PCO: 4.08±3.74 / Phenotype C PCO: 4.93±0.98 / Phenotype D PCO: 4.56±0.98 / Control: 5.41±0.77 | Phenotype A PCO: 4.56±1.13 / Phenotype B PCO: 4.15±1.10 / Phenotype C PCO: 4.52±1.11 / Phenotype D PCO: 4.58±1.05 / Control: 5.26±0.57 | Phenotype A PCO: 4.64±1.14 / Phenotype B PCO: 4.25±1.07 / Phenotype C PCO: 4.85±1.08 / Phenotype D PCO: 4.86±1.15 / Control: 5.03±0.79 | Phenotype A PCO: 3.41±1.24 / Phenotype B PCO: 3.65±1.19 / Phenotype C PCO: 3.69±1.45 / Phenotype D PCO: 3.57±1.30 / Control: 4.85±0.81 | Phenotype A PCO: 25.00±4.22 / Phenotype B PCO: 18.61±8.60 / Phenotype C PCO: 25.56±4.63 / Phenotype D PCO: 24.77±4.73 / Control: 30.77±1.35 |
| Case: 3.68 ± 1.36/ Control: 3.28 ± 1.47 | Case: 3.22 ± 1.98/ Control: 2.78 ± 1.92 | Case: 3.19 ± 1.98 / Control: 2.78 ± 1.81 | Case: 3.58 ± 2.18 / Control: 3.56 ± 2.17 | Case: 4.12 ± 1.48 / Control: 4 ± 1.39 | Case: 3.41 ± 2.42 / Control: 3.68 ± 2.57 | Case: 21.21 ± 9.64/ Control: 20.08 ± 9.43 |
| Case: 4.07±0.98/ Control: 4.25±0.95 | Case: 4.48±1.44/ Control: 5.04±1.19 | Case: 4.69±1.54/ Control: 5.29±1.17 | Case: 4.11±1.61/ Control: 4.78±1.40 | Case: 4.78±1.31/ Control: 5.22±1.10 | Case: 4.66±1.85/ Control: 4.94±1.55 | Case: 26.76±6.81/ Control: 29.51±5.83 |
| Case: 4.9±1.1/ Control: 4.3±1.2 | Case: 5.0±1.0/ Control: 5.3±0.8 | Case: 4.9±1.0/ Control: 5.2±0.9 | Case: 4.1±0.9 / Control: 4.3±1.2 | Case: 4.2±0.9/ Control: 4.4±1.0 | Case: 5.3±0.9 / Control: 5.5±0.5 | Case: 28.6±3.0/ Control: 29.3±3.1 |
| 3.78 ± 0.88 | 3.94 ± 0.84 | 4.53 ± 0.3 | 4.45 ± 0.08 | 4.71 ± 0.9 | 4.53 ± 1.02 | |
| 3.86 ± 1.35 | 2.96 ± 0.92 | 4.56 ± 0.98 | 5.52 ± 0.90 | 4.42 ± 0.83 | 4.65 ± 1.58 | 25.51 ± 2.77 |

Table 1b: FSFI domain results (continue)

| Desire | Arousal | Lubrication | Orgasm | Satisfaction | Pain | Total FSFI |
|---|--|--|--|---|---|---|
| Fertile PCO: 3.86 ± 1.34 / Infertile PCO: 4.2 ± 1.05 / fertile control: 3.69 ± 0.92 | Fertile PCO: 4.07 ± 1.31 / Infertile PCO: 4.14 ± 0.82 / fertile control: 4.09 ± 0.97 | Fertile PCO: 4.5 ± 1.04 / Infertile PCO: 4.49 ± 0.82 / fertile control: 5.07 ± 0.76 | Fertile PCO: 4.06 ± 1.45 / Infertile PCO: 4.35 ± 0.98 / fertile control: 4.41 ± 1.05 | Fertile PCO: 4.1 ± 1.91 / Infertile PCO: 4.94 ± 1.25 / fertile control: 4.93 ± 1.5 | Fertile PCO: 4.11 ± 1.08 / Infertile PCO: 4.26 ± 1.58 / fertile control: 4.43 ± 1.54 | Fertile PCO: 25.29 ± 6.58 / Infertile PCO: 26.57 ± 4.22 / fertile control: 26.8 ± 4.58 |
| Median (IQR) | Median (IQR) | Median (IQR) | Median (IQR) | Median (IQR) | Median (IQR) | Median (IQR) |
| Case: 3.60 (3.00–4.20) / Control: 3.60 (3.00–4.20) | Case: 3.90 (2.70–4.80)/ Control: 3.90 (2.70–5.02) | Case: 4.50 (3.30–5.10)/ Control: 4.80 (3.07–5.40) | Case: 4.00 (2.80–5.20)/ Control: 4.40 (3.20–5.20) | Case: 4.80 (4.00–5.60)/ Control: 4.80 (4.00–6.00) | Case: 3.60 (1.20–4.80) / Control: 3.60 (1.20–4.80) | Case: 23.70 (18.20– 28.00)/ Control: 25.25 (20.22–28.50) |
| Phenotype A PCO: 3.21±0.91/ Phenotype B PCO: 3.56±0.79 / Phenotype C PCO: 3.68±0.74 / Phenotype D PCO: 3.72±0.72 / Control: 3.81±0.85 | Phenotype A PCO: 3.80±0.93 / Phenotype B PCO: 3.84±0.86 / Phenotype C PCO: 3.88±0.81 / Phenotype D PCO: 3.79±0.92 / Control: 3.99±1.02 | Phenotype A PCO: 4.38±1.21 / Phenotype B PCO: 4.57±0.93 / Phenotype C PCO: 4.51±1.08 / Phenotype D PCO: 4.56±1.15 / Control: 4.58±1.17 | Phenotype A PCO: 3.70±0.74 / Phenotype B PCO: 3.85±0.89 / Phenotype C PCO: 3.92±0.92 / Phenotype D PCO: 3.96±0.86 / Control: 4.03±0.93 | Phenotype A PCO: 4.00±1.02 / Phenotype B PCO: 4.35±1.15 / Phenotype C PCO: 4.40±1.12 / Phenotype D PCO: 4.47±1.08 / Control: 4.54±1.27 | Phenotype A PCO: 3.98±1.13 / Phenotype B PCO: 3.98±0.87 / Phenotype C PCO: 3.96±0.93 / Phenotype D PCO: 3.97±1.04 / Control: 4.01±0.89 | Phenotype A PCO: 23.14±3.22 / Phenotype B PCO: 24.15±1.97 / Phenotype C PCO: 24.33±2.33 / Phenotype D PCO: 24.47±2.57 / Control: 24.98±3.78 |
| 3.58± 0.82 | 3.94± 0.76 | 4.48± 0.62 | 3.83± 0.98 | 4.32± 0.78 | 4.04± 0.85 | 24.19± 2.84 |
| Infertile PCO: 4.1±1.1 / Unexplained infertility: 4.0±1.0 | Infertile PCO: 2.5±0.6 / Unexplained infertility: 2.5±0.6 | | Infertile PCO: 4.9± 1.3 / Unexplained infertility: 4.9± 1.3 | Infertile PCO: 5.3± 0.9/ Unexplained infertility: 5.3± 0.9 | Infertile PCO: 5.3± 1.1 / Unexplained infertility: 5.5± 1.1 | Infertile PCO: 29.9± 4.6 / Unexplained infertility: 29.9± 4.9 |
| Median (IQR) | Median (IQR) | Median (IQR) | Median (IQR) | Median (IQR) | Median (IQR) | Median (IQR) |
| Case: 3 (3.6–4.8) / Control: 3.6 (2.4–4.8) | Case: 4.5 (3.6–5.4) / Control: 3.9 (1.3–5.1) | Case: 5.1 (4.2–6) / Control: 5.4 (2.1–6) | Case: 4.4 (3.2–5.2)/ Control: 3.8 (1.6–5.2) | Case: 4.8 (4–6) / Control: 4.2 (2.9–5.4) | Case: 5.6 (3.6–6) / Control: 4.8 (4–6) | Case: 28.5 (23–31.3) / Control: 24.9 (15.3–31.1) |
| 4.09(3.03-5.13) | 4.20(3.14-5.27) | 4.85(3.90-5.82) | 4.72(3.74-5.70) | 4.96(3.84-6.08) | 4.12(2.92-5.34) | |
| Phenotype A PCO: 3.75±0.85 / Phenotype B PCO: 3.48±0.72/ Phenotype C PCO: 3.69±0.94 / Phenotype D PCO: 3.69±0.73 / Control: 3.75±0.77 | Phenotype A PCO: 4.12±0.87 / Phenotype B PCO: 4.51±.85/ Phenotype C PCO: 4.01±1.04 / Phenotype D PCO: 4.08±0.84 / Control: 4.51±0.85 | Phenotype A PCO: 4.69±0.82 / Phenotype B PCO: 4.32±1.15/ Phenotype C PCO: 4.63±0.91 / Phenotype D PCO: 4.95±0.99 / Control: 4.89±0.86 | Phenotype A PCO: 4.68±0.903 / Phenotype B PCO: 4.106±1.22/ Phenotype C PCO: 4.43±1.02 / Phenotype D PCO: 4.66±0.92 / Control: 4.66±0.912 | Phenotype A PCO: 4.90±1.02 / Phenotype B PCO: 4.45±1.18 / Phenotype C PCO: 4.71±1.14 / Phenotype D PCO: 4.95±0.84 / Control: 4.79±0.905 | Phenotype A PCO: 2.99±1.06 / Phenotype B PCO: 3.09±1.206 / Phenotype C PCO: 3.17±0.96 / Phenotype D PCO: 3.16±1.26 / Control: 6.59±9.01 | Phenotype A PCO: 25.16±3.33 / Phenotype B PCO: 22.7±4.2 / Phenotype C PCO: 24.66±4.16 / Phenotype D PCO: 25.51±3.29 / Control: 28.78±9.49 |
| Infertile PCO: 3.94 ± 0.85 / Infertile control: 3.92 ± 0.84 | Infertile PCO: 3.92 ± 0.92 / Infertile control: 3.88 ± 0.91 | Infertile PCO: 4.41 ± 0.85 / Infertile control: 4.49 ± 0.73 | Infertile PCO: 3.5 ± 0.8 / Infertile control: 3.49 ± 0.84 | Infertile PCO: 4.78 ± 1.19 / Infertile control: 4.92 ± 1.05 | Infertile PCO: 4.64 ± 1.13 / Infertile control: 4.80 ± 1.16 | Infertile PCO: 25.13 ± 3.95 / Infertile control: 25.35 ± 3.87 |
| 3.69 ± 1.09 | 3.49 ± 1.32 | 3.82 ± 1.53 | 2.93 ± 1.36 | 3.82 ± 1.35 | 4.83 ± 1.06 | 22.95 ± 5.77 |
| Case: 3.4 ± 1.2/ Control: 3.6 ± 1.2 | Case: 3.9 ± 1.1/ Control: 4.2 ± 1.1 | Case: 4.7 ± 0.6/ Control: 5.7 ± 8.5 | Case: 4.5 ± 0.7/ Control: 5.4 ± 7.6 | Case: 2.8 ± 1.2/ Control: 4.1 ± 1.6 | Case: 5.8 ± 1.4/ Control: 5.3 ± 1.2 | Case: 25.0 ± 3.3/ Control: 28.2 ± 16.1 |

Table 1b: FSFI domain results (continue)

| Desire | Arousal | Lubrication | Orgasm | Satisfaction | Pain | Total FSFI |
|--|---|--|--|--|--|---|
| Fertile PCO: 3.93± 0.80 / Infertile PCO: 3.60±0.95 | Fertile PCO: 3.94± 0.72 / Infertile PCO: 3.36±0.98 | Fertile PCO: 4.54± 1.16 / Infertile PCO: 4.03±1.26 | Fertile PCO: 4.38± 1.01 / Infertile PCO:2.72±1.09 | Fertile PCO: 5.07± 2.20 / Infertile PCO: 4.34±1.11 | Fertile PCO: 3.95± 1.46 / Infertile PCO: 3.98±1.26 | Fertile PCO: 25.81± 4.39 / Infertile PCO: 22.03±4.77 |
| All PCO Cases: 4.25±2.15 / phenotype A PCO: 4.41±2.16 / Phenotype B PCO: 3.98±2.01 /Phenotype C PCO: 4.26±2.35 /Phenotype D PCO: 4.13±2.09 /Control: 3.89±2.09 | All PCO Cases: 6.98±9.54 / phenotype A PCO: 7.77±9.74 / Phenotype B PCO: 6.00±9.77 /Phenotype C PCO: 4.87±8.59 /Phenotype D PCO: 10.63±9.38 /Control: 5.86±8.71 | All PCO Cases: 3.18±4.26 / phenotype A PCO: 3.64±4.40 / Phenotype B PCO: 2.60±4.20 /Phenotype C PCO: 1.92±3.59 /Phenotype D PCO: 5.50±4.27 /Control: 2.49±3.94 | All PCO Cases: 3.38±4.85 / phenotype A PCO: 4.10±5.52 / Phenotype B PCO: 2.57±4.36 /Phenotype C PCO: 2.08±3.83 /Phenotype D PCO: 5.25±4.14 /Control: 2.69±3.95 | All PCO Cases: 4.38±5.95 / phenotype A PCO: 5.10±6.34 / Phenotype B PCO: 3.52±5.68 /Phenotype C PCO: 2.92±5.35 /Phenotype D PCO: 6.63±5.45 /Control: 3.86±5.78 | All PCO Cases: 4.03±5.57 / phenotype A PCO: 4.74±6.00 / Phenotype B PCO: 3.21±5.31 /Phenotype C PCO: 2.39±4.65 /Phenotype D PCO: 6.69±5.10 /Control: 3.62±5.28 | All PCO Cases: 26.33±30.71 / phenotype A PCO: 29.94±32.27 / Phenotype B PCO: 21.83±30.60 /Phenotype C PCO: 18.58±26.37 /Phenotype D PCO: 39.25±28.94 / Control: 22.21±28.24 |
| Case: 3.4±1.3/ Control: 4.3±1.6 | Case: 3.9±1.5 / Control: 5.3±1.6 | Case: 4.4±1.2/ Control: 5.1±1.5 | Case: 4.5±1.3 / Control: 4.9±1.3 | Case: 4.4±1.3 / Control: 5.4±1.6 | Case: 4.6±1.6/ Control: 5.7±1.8 | Case: 25.4±4 / Control: 30.9±4.5 |




Figure 2: The pooled prevalence of SD in women with PCO is estimated as 73%

The results showed that the country is not a source of heterogeneity (coefficient=-0.34, standard error=0.036, $p=0.35$).

The pooled SMD of desire subscale of FSFI (case-control) estimated as -0.14 (95% -0.30, 0.02) ($I^2=86.9\%$, $P<0.001$) (Figure 7).

The pooled SMD of arousal subscale of FSFI (case-control) estimated as -0.34 (95% -0.58, -0.09) ($I^2=94.7\%$, $P<0.001$) (Figure 8).

The pooled SMD of lubrication subscale of FSFI (case-control) estimated as -0.37 (95% -0.56, -0.19) ($I^2=90.6\%$, $P<0.001$) (Figure 9).




Figure 3: The pooled odds of SD in women with PCO is estimated as 2.45




Figure 4: The pooled odds of SD in women with PCO is estimated as 2.45

The pooled SMD of orgasm subscale of FSFI (case-control) estimated as -0.31(95% -0.46, -0.15) ($I^2=86.2\%$, $P<0.001$) (Figure 10).

The pooled SMD of satisfaction subscale of FSFI (case-control) estimated as -0.25(95% -0.38, -0.12) ($I^2=80.5\%$, $P<0.001$) (Figure 11).




Figure 5: The pooled SMD of total FSFI is estimated as -0.48 (case-control)




Figure 6: The funnel plot showing no evidence of publication bias

The pooled SMD of pain subscale of FSFI ($I^2=90.6\%$, $P<0.001$) (Figure 12). (case-control) estimated as $-0.35(95\% -0.54, -0.17)$




Figure 7: The pooled SMD of desire subscale of FSFI is estimated as -0.14 (case-control)




Figure 8: The pooled SMD of arousal subscale of FSFI is estimated as -0.34 (case-control)

Discussion

To our knowledge, this is the most comprehensive systematic review and meta-analysis to date that includes original studies utilizing the FSFI questionnaire to assess sexual dysfunction (SD) in women with PCOS. A total of 37 studies employing

the FSFI were included.

We estimated the pooled prevalence and odds of developing SD in women with PCOS compared to healthy controls, as well as the pooled standardized mean difference (SMD) for total FSFI scores and its subscales.




Figure 9: The pooled SMD of arousal subscale of FSFI is estimated as -0.34 (case-control)




Figure 10: The pooled SMD of orgasm subscale of FSFI is estimated as -0.31(case-control)

Our findings showed that the pooled SMD for total FSFI was -0.48 (95% CI: -0.72 to -0.25), and all FSFI subdomains demonstrated statistically

significant differences between women with PCOS and controls.




Figure 11: The pooled SMD of satisfaction subscale of FSFI is estimated as -0.31(case-control)




Figure 12: The pooled SMD of pain subscale of FSFI is estimated -0.35(case-control)

Higher levels of heterogeneity between the results of included studies could be due to various diagnostic criteria, FSFI cut-offs, and different populations with diverse cultures.

A recent systematic review that included 32 articles (of which only 20 used the FSFI) reported a pooled SMD of -0.75 (95% CI: -1.37 to -0.12). In that study, all FSFI subscales except for the desire domain showed significant differences between women with PCOS and controls (49).

In another systematic review and meta-analysis which is published in 2020, Loh et al included 12 studies that used the FSFI, and reported no significant difference between the pooled total FSFI, and its subscales in women with and without PCO, except for pain and satisfaction which were worse in PCO group than controls (50).

Our results also showed the pooled odds of developing SD in women with PCO is 2.45 (95% CI: 1.55 - 3.86), showing that women with PCO are at higher risk of worse sexual function. In a study in Turkey, Aba et al reported lower FSFI in women with PCO than in controls, and the odds of SD were more than three times in cases than controls (15).

Majahed et al. reported that 72% of women with PCOS had sexual dysfunction (SD) and exhibited higher levels of depression and reduced sexual quality of life compared with controls (18). Diamond et al., in a study conducted in the United States, found no significant difference in FSFI scores between women diagnosed with PCOS and those without the condition (38) which is in agreement with Shafiti et al findings (17). The underlying mechanisms of sexual dysfunction (SD) in women with PCOS are not fully understood. However, the coexistence of various physical and psychological factors—such as hirsutism, obesity, insulin resistance, depression, anxiety, and infertility—may collectively contribute to a diminished quality of life in this population (51). Women with PCO have a higher prevalence of infertility, which may negatively influence their sexual functioning and marital relationships (52). Factors such as menstrual irregularities, obesity, infertility, and hirsutism may contribute to reduced self-esteem and emotional distress, which in turn can predispose women with PCOS to sexual dysfunction (SD) (53). Trent et al. reported that young women with PCOS were less sexually active and expressed

greater concern about fertility than their healthy counterparts, factors that collectively impacted their quality of life (54). The study found that women with PCOS had 2.8-fold lower sexual activity compared with healthy controls. Furthermore, hormonal alterations, particularly elevated androgen levels, may contribute to the development of sexual dysfunction (SD). Evidence suggests that anti-androgen therapy in these women can improve sexual pain, orgasm, and satisfaction (55).

For the evaluation of sexual dysfunction, it is important to consider that its assessment is culturally influenced and can be challenging to conduct across different countries.

This study has several strengths. First, the number of included studies was relatively high, providing a robust evidence base. Second, the assessment of publication bias indicated that no relevant studies were missed in this systematic review. Third, we estimated both the pooled odds ratio for developing sexual dysfunction (SD) in women with PCOS and the standardized mean difference (SMD) across all FSFI subscales. Finally, we explored potential sources of heterogeneity by evaluating the effects of country of origin and year of publication.

Our findings suggest that sexual dysfunction is highly prevalent among women with PCO, driven by both biological and psychosocial factors. Future research should adopt longitudinal and interventional designs to clarify causality and evaluate targeted management strategies.

Conclusion

This meta-analysis demonstrates a significantly higher prevalence of sexual dysfunction in women with PCO, emphasizing the need for routine sexual health assessment and holistic management, including psychological support, hormonal regulation, and lifestyle interventions.

Conflict of Interests

Authors declare no conflict of interests.

Acknowledgments

None.

References

1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. *J Clin Endocrinol Metab.* 2004;89(6):2745-9.
2. Ehrmann DA. Polycystic ovary syndrome. *N Engl J Med.* 2005;352(12):1223-36.
3. Shahraki Z, Rastkar M, Ramezanpour MR, Ghajarzadeh M. The prevalence and odds of bipolar disorder in women with polycystic ovary syndrome (PCO) disease: a systematic review and meta-analysis. *Arch Womens Ment Health.* 2024;27(3):329-36.
4. Davari-Tanha F, Hosseini Rashidi B, Ghajarzadeh M, Noorbala AA. Bipolar disorder in women with polycystic ovarian syndrome (PCO). *Acta Med Iran.* 2014;52(1):46-8.
5. Hahn S, Janssen OE, Tan S, Pleger K, Mann K, Schedlowski M, Kimmig R, Benson S, Balamitsa E, Elsenbruch S. Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome. *Eur J Endocrinol.* 2005;153(6):853-60.
6. Elsenbruch S, Hahn S, Kowalsky D, Offner AH, Schedlowski M, Mann K, Janssen OE. Quality of life, psychosocial well-being, and sexual satisfaction in women with polycystic ovary syndrome. *J Clin Endocrinol Metab.* 2003;88(12):5801-7.
7. Deniz A, Kehribar DY. Evaluation of sexual functions in infertile women with polycystic ovary syndrome. *Niger J Clin Pract.* 2020;23(11):1548-55.
8. Mojahed BS, Ghajarzadeh M, Khammar R, Shahraki Z. Depression, sexual function and sexual quality of life in women with polycystic ovary syndrome (PCOS) and healthy subjects. *J Ovarian Res.* 2023;16(1):105.
9. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *Int J Surg.* 2021;88:105906.
10. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. Newcastle-Ottawa quality assessment scale cohort studies. University of Ottawa; 2014. Available from: http://www.ohri.ca/programs/clinical_epidemiology/sgen.pdf.
11. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol.* 2010;25(9):603-5.
12. Uzel K, Uluğ P, Kiremitli T, Kiremitli S, Başol G. Anxiety, quality of life, eating behaviors, and sexual life in women with polycystic ovary syndrome. *Zeynep Kamil Med J.* 2021;52(3):152-9.
13. Hashemi S, Ramezani Tehrani F, Farahmand M, Bahri Khomami M. Association of PCOS and its clinical signs with sexual function among Iranian women affected by PCOS. *J Sex Med.* 2014;11(10):2508-14.

14. Kogure GS, Ribeiro VB, Lopes IP, Furtado CLM, Kodato S, Silva de Sá MF, Ferriani RA, Lara LADS, Maria Dos Reis R. Body image and its relationships with sexual functioning, anxiety, and depression in women with polycystic ovary syndrome. *J Affect Disord.* 2019;253:385-93.
15. Aba YA, Aytek Şik B. Body image and sexual function in women with polycystic ovary syndrome: a case-control study. *Rev Assoc Med Bras* (1992). 2022;68(9):1264-9.
16. Ferraresi SR, Lara LA, Reis RM, Rosa e Silva AC. Changes in sexual function among women with polycystic ovary syndrome: a pilot study. *J Sex Med.* 2013;10(2):467-73.
17. Shafti V, Shahbazi S. Comparing sexual function and quality of life in polycystic ovary syndrome and healthy women. *J Family Reprod Health.* 2016;10(2):92-8.
18. Mojahed BS, Ghajarzadeh M, Khammar R, Shahraki Z. Depression, sexual function and sexual quality of life in women with polycystic ovary syndrome (PCOS) and healthy subjects. *J Ovarian Res.* 2023;16(1):105.
19. Akbari Sene A, Tahmasbi B, Keypour F, Zamanian H, Golbabaei F, Amini-Tehrani M. Differences in and correlates of sexual function in infertile women with and without polycystic ovary syndrome. *Int J Fertil Steril.* 2021;15(1):65-72.
20. Ashrafi M, Jahangiri N, Jahanian Sadatmahalleh S, Mirzaei N, Gharagozloo Hesari N, Rostami F, Mousavi SS, Zeinaloo M. Does prevalence of sexual dysfunction differ among the most common causes of infertility? A cross-sectional study. *BMC Womens Health.* 2022;22(1):140.
21. Daescu AC, Dehelean L, Navolan DB, Gaitoane AI, Daescu A, Stoian D. Effects of hormonal profile, weight, and body image on sexual function in women with polycystic ovary syndrome. *Healthcare (Basel).* 2023;11(10):1488.
22. Deniz A, Kehribar DY. Evaluation of sexual functions in infertile women with polycystic ovary syndrome. *Niger J Clin Pract.* 2020;23(11):1548-54.
23. Yarjanli M, Jahanian Sadatmahalleh S, Mirzaei N, Azarbajani K. Female sexual function in different phenotypes of polycystic ovarian syndrome: a comparative cross-sectional study. *Sci Rep.* 2022;12(1):19317.
24. Lara LA, Ramos FK, Kogure GS, Costa RS, Silva de Sá MF, Ferriani RA, dos Reis RM. Impact of physical resistance training on the sexual function of women with polycystic ovary syndrome. *J Sex Med.* 2015;12(7):1584-90.
25. Mantzou D, Stamou MI, Armeni AK, Roupas ND, Assimakopoulos K, Adonakis G, et al. Impaired sexual function in young women with PCOS: the detrimental effect of anovulation. *J Sex Med.* 2021;18(11):1872-9.
26. Battaglia C, Nappi RE, Mancini F, Cianciosi A, Persico N, Busacchi P, et al. PCOS, sexuality, and clitoral vascularisation: a pilot study. *J Sex Med.* 2008;5(12):2886-94.
27. Drosdzol A, Skrzypulec V, Mazur B, Pawlińska-Chmara R. Quality of life and marital sexual satisfaction in women with polycystic ovary syndrome. *Folia Histochem Cytobiol.* 2007;45 Suppl 1:S93-7.
28. Ercan CM, Coksuer H, Aydogan U, Alanbay I, Keskin U, Karasahin KE, et al. Sexual dysfunction assessment and hormonal correlations in patients with polycystic ovary syndrome. *Int J Impot Res.* 2013;25(4):127-32.
29. Eftekhari T, Sohrabvand F, Zabandan N, Shariat M, Haghollahi F, Ghahghaei-Nezamabadi A. Sexual dysfunction in patients with polycystic ovary syndrome and its affected domains. *Iran J Reprod Med.* 2014;12(8):539-46.
30. Veras AB, Bruno RV, de Avila MA, Nardi AE. Sexual dysfunction in patients with polycystic ovary syndrome: clinical and hormonal correlations. *Compr Psychiatry.* 2011;52(5):486-9.
31. Dashti S, Latiff LA, Hamid HA, Sani SM, Akhtari-Zavare M, Abu Bakar AS, et al. Sexual dysfunction in patients with polycystic ovary syndrome in Malaysia. *Asian Pac J Cancer Prev.* 2016;17(8):3747-51.
32. Pastoor H, Both S, Laan ETM, Laven JSE. Sexual dysfunction in women with PCOS: a case control study. *Hum Reprod.* 2023;38(11):2230-8.
33. Aydogan Kirmizi D, Baser E, Onat T, Demir Caltekin M, Yalvac ES, Kara M, et al. Sexual function and depression in polycystic ovary syndrome: Is it associated with inflammation and neuromodulators? *Neuropeptides.* 2020;84:102099.
34. Noroozzadeh M, Tehrani FR, Mobarakabadi SS, Farahmand M, Dovom MR. Sexual function and hormonal profiles in women with and without polycystic ovary syndrome: a population-based study. *Int J Impot Res.* 2017;29(1):1-6.
35. Fliegner M, Richter-Appelt H, Krupp K, Brunner F. Sexual function and socio-sexual difficulties in women with polycystic ovary syndrome (PCOS). *Geburtshilfe Frauenheilkd.* 2019;79(5):498-509.
36. Tian X, Ruan X, Du J, Cheng J, Ju R, Mueck AO. Sexual function in Chinese women with different clinical phenotypes of polycystic ovary syndrome. *Gynecol Endocrinol.* 2023;39(1):2221736.
37. Tian X, Ruan X, Du J, Wang J, Yin D, Cheng J, et

- al. Sexual function in Chinese women with polycystic ovary syndrome and correlation with clinical and biochemical characteristics. *Reprod Sci*. 2021;28(11):3181-92.
38. Diamond MP, Legro RS, Coutifaris C, Alvero R, Robinson RD, Casson PA, et al. Sexual function in infertile women with polycystic ovary syndrome and unexplained infertility. *Am J Obstet Gynecol*. 2017;217(2):191.e1-191.e19.
39. Kępczyńska-Nyk A, Kuryłowicz A, Nowak A, Bednarczuk T, Ambroziak U. Sexual function in women with androgen excess disorders: classic forms of congenital adrenal hyperplasia and polycystic ovary syndrome. *J Endocrinol Invest*. 2021;44(3):505-13.
40. Bazarganipour F, Ziaei S, Montazeri A, Foroozanfard F, Kazemnejad A, Faghihzadeh S. Sexual functioning among married Iranian women with polycystic ovary syndrome. *Int J Fertil Steril*. 2014;8(3):273-80.
41. Bahadori F, Jahanian Sadatmahalleh S, Montazeri A, Nasiri M. Sexuality and psychological well-being in different polycystic ovary syndrome phenotypes compared with healthy controls: a cross-sectional study. *BMC Womens Health*. 2022;22(1):390.
42. Basirat Z, Faramarzi M, Esmaelzadeh S, Abedi Firoozjai SH, Mahouti T, Geraili Z. Stress, depression, sexual function, and alexithymia in infertile females with and without polycystic ovary syndrome: a case-control study. *Int J Fertil Steril*. 2019;13(3):203-8.
43. Fereidooni B, Jenabi E, Khazaei S, Abdoli S. The effective factors on the sexual function of polycystic ovary syndrome women: a cross-sectional study. *Int J Fertil Steril*. 2022;16(3):220-3.
44. Benetti-Pinto CL, Ferreira SR, Antunes A Jr, Yela DA. The influence of body weight on sexual function and quality of life in women with polycystic ovary syndrome. *Arch Gynecol Obstet*. 2015;291(2):451-5.
45. Frouhari S, Doryanizadeh L, Farahi F, Namavar Jahromi B, Nourimand F. Sexual function in fertile and infertile women with polycystic ovary syndrome. *International Journal of Pharmaceutical Research*. 2019;11(3).
46. Cetinkaya Altuntas S, Celik O, Ozer U, Colak S. Depression, anxiety, body image scores, and sexual dysfunction in patients with polycystic ovary syndrome according to phenotypes. *Gynecol Endocrinol*. 2022;38(10):849-55.
47. Gateva A, Kamenov Z. Sexual function in patients with PCOS and/or obesity before and after metformin treatment. *Advances in Sexual Medicine*. 2012;2:25-9.
48. Davari-Tanha F, Asadi M, Shahraki Z, Assaf Z, Kaveh Z, Ghajarzadeh M. Sexual dysfunction in polycystic ovarian syndrome patients. *J Obstet Gynecol Cancer Res*. 2024;9(2):161-6.
49. Pastoor H, Mousa A, Bolt H, Bramer W, Burgert TS, Dokras A, et al. Sexual function in women with polycystic ovary syndrome: a systematic review and meta-analysis. *Hum Reprod Update*. 2024;30(3):323-40.
50. Loh HH, Yee A, Loh HS, Kanagasundram S, Francis B, Lim LL. Sexual dysfunction in polycystic ovary syndrome: a systematic review and meta-analysis. *Hormones (Athens)*. 2020;19(3):413-23.
51. Cooney LG, Lee I, Sammel MD, Dokras A. High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis. *Hum Reprod*. 2017;32(5):1075-91.
52. Joham AE, Teede HJ, Ranasinha S, Zoungas S, Boyle J. Prevalence of infertility and use of fertility treatment in women with polycystic ovary syndrome: data from a large community-based cohort study. *J Womens Health (Larchmt)*. 2015;24(4):299-307.
53. Castelo-Branco C, Naumova I. Quality of life and sexual function in women with polycystic ovary syndrome: a comprehensive review. *Gynecol Endocrinol*. 2020;36(2):96-103.
54. Trent ME, Rich M, Austin SB, Gordon CM. Fertility concerns and sexual behavior in adolescent girls with polycystic ovary syndrome: implications for quality of life. *J Pediatr Adolesc Gynecol*. 2003;16(1):33-37.
55. Conaglen HM, Conaglen JV. Sexual desire in women presenting for antiandrogen therapy. *J Sex Marital Ther*. 2003;29(4):255-67.

Citation: Shahraki Z, Rastkar M, Rastkar E, Mohamadi A, Mohammadghasemi M, Ghajarzadeh M. **Prevalence and Odds of Developing Sexual Dysfunction in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.** *J Family Reprod Health* 2025; 19(4): 247-64.